Literature DB >> 6603629

Low plasma 25-hydroxyvitamin D and serum calcium levels in institutionalized epileptic subjects: associated risk factors, consequences and response to treatment with vitamin D.

M W Davie, C E Emberson, D E Lawson, G E Roberts, J L Barnes, N D Barnes, A F Heeley.   

Abstract

In a survey of 108 subjects with a history of epilepsy in a hospital for the mentally handicapped, administration of both phenobarbitone and phenytoin was associated with low serum calcium and plasma 25-hydroxyvitamin D (25-(OH)D) levels in female subjects only. Intake of phenytoin (as mg/kg body weight) in female subjects exceeded that in males by 22 per cent, whilst the intake of phenobarbitone was 37 per cent higher. The doses of phenobarbitone and phenytoin were each inversely related to plasma 25-(OH)D concentration, but anticonvulsant drug dosage did not correlate with the magnitude of the decline of plasma 25-(OH)D concentration in winter (November-February). No influence of sodium valproate was detected on serum calcium or on plasma 25-(OH)D levels. Limited exposure to ultraviolet irradiation (UVR) or oral administration of vitamin D restored plasma 25-(OH)D to normal levels and healed osteomalacia in a subject with tuberous sclerosis. In this subject, fit frequency declined in response to UVR and to a lesser extent in response to oral vitamin D, despite the attainment of similar levels of serum calcium and of plasma 25-(OH)D. Serum calcium levels in the other 108 subjects were lower in those experiencing the most frequent fits, but serum calcium could not be restored to levels found in subjects not receiving anticonvulsant drugs unless supraphysiological doses of vitamin D were given. Vitamin D deficiency in the epileptic population receiving drugs was assessed by the response of alkaline phosphatase to vitamin D administration. A consistent fall of serum alkaline phosphatase was found only if the initial level exceeded 175 per cent of the normal value established by reference to a population not receiving phenobarbitone or phenytoin. By this criterion five out of 45 subjects (11 per cent), aged nine to 36 years were vitamin D deficient.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6603629

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  6 in total

1.  The Association Between Antiepileptic Drugs and Bone Disease.

Authors:  Alison M. Pack
Journal:  Epilepsy Curr       Date:  2003-05       Impact factor: 7.500

2.  Factors associated with the biochemical changes in vitamin D and calcium metabolism in institutionalized patients with epilepsy.

Authors:  H Gough; A Bissesar; T Goggin; D Higgins; M Baker; M Crowley; N Callaghan
Journal:  Ir J Med Sci       Date:  1986-06       Impact factor: 1.568

Review 3.  Adverse effects of antiepileptic drugs on bone structure: epidemiology, mechanisms and therapeutic implications.

Authors:  A M Pack; M J Morrell
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

4.  Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy.

Authors:  Sina Nettekoven; Alexander Ströhle; Birgit Trunz; Maike Wolters; Susanne Hoffmann; Rüdiger Horn; Martin Steinert; Georg Brabant; Ralf Lichtinghagen; Hans-Jürgen Welkoborsky; Ingrid Tuxhorn; Andreas Hahn
Journal:  Eur J Pediatr       Date:  2008-02-13       Impact factor: 3.183

Review 5.  Drug-vitamin D interactions: a systematic review of the literature.

Authors:  Kim Robien; Sarah J Oppeneer; Julia A Kelly; Jill M Hamilton-Reeves
Journal:  Nutr Clin Pract       Date:  2013-01-10       Impact factor: 3.080

6.  How Antiepileptics May Change the Serum Level of Vitamin D, Calcium, and Phosphorus in Children with Epilepsy.

Authors:  Sasan Saket; Neda Varasteh; Ali Asghar Halimi Asl; Hedyeh Saneifard
Journal:  Iran J Child Neurol       Date:  2021
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.